Interstitial Lung Disease Trial, Recruiting (NCT07466420)

Interstitial Lung Disease Trial, Recruiting NCT07466420 Sponsor: Katerina M. Antoniou Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07466420 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with IPF (a type of lung scarring disease) or a related condition called Fibrotic ILD (scarring of the lung tissue).
People who are already taking standard approved lung treatments, either nintedanib or pirfenidone, or immune-suppressing medications, as these are permitted to continue during the trial.

Who may not be able to join:

People whose breathing test shows a FeNO reading above 25 ppb — this is a measurement of airway inflammation that may indicate another lung condition such as asthma is present (confirm with trial site).
People who do not start taking the trial supplement quercetin within the first week after their initial baseline appointment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Katerina M. Antoniou, MD PhD, Professor, Department of Respiratory Medicine, University Hospital of Heraklion, School of Medicine, University of Crete

Phone: +302810371966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07466420

Sponsor: Katerina M. Antoniou

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: +302810371966

More information: https://clinicaltrials.gov/study/NCT07466420

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with IPF (a type of lung scarring disease) or a related condition called Fibrotic ILD (scarring of the lung tissue).
People who are already taking standard approved lung treatments, either nintedanib or pirfenidone, or immune-suppressing medications, as these are permitted to continue during the trial.

Who may not be able to join:

People whose breathing test shows a FeNO reading above 25 ppb — this is a measurement of airway inflammation that may indicate another lung condition such as asthma is present (confirm with trial site).
People who do not start taking the trial supplement quercetin within the first week after their initial baseline appointment.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Katerina M. Antoniou

Registry

ClinicalTrials.gov

Start date

26 January 2026

Est. completion

31 January 2028

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Change in Blood Leukocyte Telomere length; Change in FeNO measurement; Change in FVC (mL); Change in FVC%; Change in Diffusion Capacity for Carbon Monoxide (DLCO); Change in the Senescence-Associated Secretory Phenotype (SASP)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov